Pamela N. Munster

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects...

Treatment-emergent adverse events will be a primary outcome measure for the following groups: Phase 1 Dose Exploration Part 1 monotherapy Phase 1 Dose Expansion Part 2 monotherapy Phase 1 combination arm with AMG 510 and anti P...

Recruiting

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...

A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related

Recruiting

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.

Recruiting

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy

Recruiting

9-ING-41 in Patients With Advanced Cancers

The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.

Recruiting

AO-176 in Multiple Solid Tumor Malignancies

Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.

Recruiting

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Sol...

Identify nature and frequency of dose limiting toxicities

Recruiting

Study of ORIC-101 in Combination With Anticancer Therapy

RP2D as determined by 3+3 dose escalation design

Recruiting

A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in H...

Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in patients with advanced prostate cancer).

Recruiting